TRDA
NASDAQEntrada Therapeutics Inc.
Price$4.37-0.35 (-7.51%)
01:30 PM07:45 PM
News · 26 weeks48-80%
2026-04-192026-10-11
Mix2790d
- Insider16(59%)
- Other6(22%)
- SEC Filings5(19%)
Latest news
25 items- SECSEC Form 8-K filed by Entrada Therapeutics Inc.8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- PRIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1. ELEVATE-44-201 is a Phase
- PREntrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and functional benefit in future cohorts while maintaining a convenient Q6W dosing schedule -- -- ELEVATE-45-201 Cohort 2 enrollment is complete and the Company is on track to report data at the increased dos
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Entrada Therapeutics Inc.SCHEDULE 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
- PREntrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved. An Independent Grant Review Committee, consisting of neuromuscular specialists, patient advocates and health equity advocates, is re
- INSIDERLarge owner Mpm Bioventures 2018, L.P. sold $1,905,768 worth of shares (259,837 units at $7.33) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2014, L.P. sold $1,905,768 worth of shares (259,837 units at $7.33) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2018, L.P. sold $617,379 worth of shares (86,482 units at $7.14) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2014, L.P. sold $617,379 worth of shares (86,482 units at $7.14) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERPresident, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 2,079 shares, decreasing direct ownership by 0.96% to 214,238 units (SEC Form 4) to cover withholding tax4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERCEO Doshi Dipal covered exercise/tax liability with 8,724 shares, decreasing direct ownership by 2% to 517,290 units (SEC Form 4) to satisfy withholding tax4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERPresident & COO Dowden Nathan J covered exercise/tax liability with 2,528 shares, decreasing direct ownership by 1% to 196,060 units (SEC Form 4) to cover taxes4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERChief Financial Officer Wentworth Kory James covered exercise/tax liability with 1,733 shares, decreasing direct ownership by 1% to 117,277 units (SEC Form 4) (for tax liability)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- PREntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units ("RSUs") and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the Company's common stock on August 31, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employ
- INSIDERLarge owner Mpm Bioventures 2018, L.P. sold $615,777 worth of shares (86,914 units at $7.08) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2014, L.P. sold $615,777 worth of shares (86,914 units at $7.08) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2014, L.P. sold $461,546 worth of shares (62,714 units at $7.36) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2018, L.P. sold $461,546 worth of shares (62,714 units at $7.36) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERDirector Parmar Kush sold $1,078,937 worth of shares (155,255 units at $6.95) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERLarge owner 5am Ventures V, L.P. sold $431,829 worth of shares (62,811 units at $6.88) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SECAmendment: SEC Form 144/A filed by Entrada Therapeutics Inc.144/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
- SECSEC Form 10-Q filed by Entrada Therapeutics Inc.10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECEntrada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- PREntrada Therapeutics Reports Second Quarter 2026 Financial Results-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates. "With multiple data readouts ahead in 2026,
- INSIDERLarge owner 5am Ventures V, L.P. sold $807,027 worth of shares (116,474 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
TRDA FAQ
7 questionsWhat does Entrada Therapeutics Inc. do?
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to...Where does TRDA stock trade?
Entrada Therapeutics Inc. (TRDA) is listed on NASDAQ.What sector and industry is TRDA in?
Entrada Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Entrada Therapeutics Inc. go public?
Entrada Therapeutics Inc. (TRDA) completed its IPO in 2021.What are analysts saying about TRDA?
Entrada Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-05-08. Recent price targets range from $2000.00 to $2900.00.What companies are similar to TRDA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TRDA side-by-side with any of them on Quantisnow.How can I track TRDA on Quantisnow?
Quantisnow aggregates Entrada Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRDA to receive live email and push alerts on every new disclosure.